Cita APA

Pavord, I., Bourdin, A., Papi, A., Domingo, C., Corren, J., Altincatal, A., . . . Hardin, M. (2023). Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of ICS dose.

Citación estilo Chicago

Pavord, ID, et al. Dupilumab Sustains Efficacy in Patients With Moderate-to-severe Type 2 Asthma Regardless of ICS Dose. 2023.

Cita MLA

Pavord, ID, et al. Dupilumab Sustains Efficacy in Patients With Moderate-to-severe Type 2 Asthma Regardless of ICS Dose. 2023.